Kennedy Defends Trump’s Disputed Claims on Drug Price Reductions

In a spirited defense of President Trump’s mathematical claims, Health Secretary Robert F. Kennedy Jr. told senators that the president simply “has a different way of calculating” when discussing prescription drug price reductions.

During testimony before the Senate Finance Committee on Wednesday, Kennedy attempted to justify Trump’s frequent statements about drug price discounts that mathematicians and economists have flagged as impossible.

“If you have a $600 drug, and you reduce it to $10, that’s a 600 percent reduction,” Kennedy told the committee. His statement came in response to questioning from Senator Elizabeth Warren (D-Massachusetts) about the administration’s TrumpRx prescription drug service.

Kennedy’s explanation, however, contradicts basic mathematical principles. A price reduction from $600 to $10 would represent a discount of approximately 98.3 percent. By definition, price discounts cannot exceed 100 percent, as this would mean the product is free or that consumers would be paid to take it.

Warren had been questioning Kennedy about specific medications on the TrumpRx platform, comparing their prices to generic alternatives available at retailers like Costco. The senator highlighted cases where Americans using TrumpRx were still paying significantly more than alternatives available elsewhere in the market.

The exchange underscored ongoing controversy surrounding the administration’s claims about its prescription drug pricing initiatives. Warren took aim at Trump’s recurring statements about TrumpRx offering discounts ranging from 400 to 1,500 percent, saying such figures would mean “companies should be paying you to take their drugs.”

President Trump has made these mathematically contentious claims since launching deals with pharmaceutical companies last year. The president has expressed frustration with media coverage of these initiatives, complaining in January that he “got the biggest price reduction in history on drugs, pharmaceutical, and I can’t get these guys to talk about it.”

As criticism of his percentage claims mounted, Trump began introducing qualifiers to his statements. “You could say it’s an 80 percent reduction,” Trump said earlier this year. “Or you could say it’s a 1,000 percent reduction. You could say whatever you want.”

The president has continued making similar assertions as recently as March 25, when he stated: “We have lowered the price of drugs by 50, 60, 70 and 80 and 90 percent. And there’s another way of figuring, you could also say, depending on the way you phrased the statement, 400, 500, 600, 700 percent. Nobody’s ever seen anything like it.”

These claims arrive amid broader national concerns about prescription drug affordability. The pharmaceutical industry has faced intense scrutiny over pricing practices, with many Americans struggling to afford necessary medications. Various policy proposals from both political parties have attempted to address these concerns, with mixed results.

TrumpRx represents one of the administration’s signature efforts to tackle drug pricing, though independent analyses suggest its impact has been limited and uneven across different medications and patient populations.

Healthcare economists note that while any price reductions are welcome for consumers facing high medication costs, accurate representation of savings percentages is important for transparency and for consumers trying to make informed healthcare decisions.

The mathematical dispute highlights the challenges of communicating complex healthcare policy changes to the public, as well as the political sensitivities surrounding healthcare costs in an election year when affordability remains a top concern for voters.

As the hearing continued, lawmakers pressed Kennedy on other aspects of the administration’s healthcare policies, but his defense of the president’s unique mathematical approach sparked particular attention from observers of the ongoing debate over prescription drug pricing in America.